Order DYSPORT® for Clinics

DYSPORT® (abobotulinumtoxinA) is an injectable botulinum toxin type A supplied as a sterile powder for reconstitution, stocked by licensed clinics and medical professionals in 300 Unit and 500 Unit vials. Under FDA-approved labeling it is indicated for temporary improvement of moderate to severe glabellar lines in adults under 65, for cervical dystonia in adults, and for upper and lower limb spasticity in adults and in pediatric patients aged 2 years and older. Most teams match vial size to weekly treatment volume, because reconstituted product is refrigerated and used within a short window rather than held as working stock.

How abobotulinumtoxinA works and where it fits in practice

Botulinum toxin type A blocks the release of acetylcholine at the neuromuscular junction. The treated muscle contracts less, which softens dynamic lines in aesthetic use and reduces abnormal muscle tone or pulling in cervical dystonia and spasticity. The effect is local, dose-dependent and temporary, so treatment is planned as a repeating series rather than a one-time procedure.

In aesthetic practice, Dysport sits alongside other neuromodulators in the upper-face toolkit and is injected into the glabellar complex using the pattern described in the prescribing information. In rehabilitation and neurology settings, it is used as part of a wider spasticity or dystonia plan that may also include physical therapy, bracing and oral agents. Injection technique, muscle selection and dose distribution belong to the treating clinician and the labeled dosing tables.

Onset and duration vary by indication, dose and the muscle treated, so clinics usually build follow-up and retreatment intervals into the booking workflow. For glabellar lines, the labeling states that retreatment should be no more frequent than every three months.

Labeled indications and professional-use context

Dysport is a product for administration by trained healthcare professionals in a clinical setting, not for self-administration. Labeled uses include:

• Temporary improvement in the appearance of moderate to severe glabellar lines in adults younger than 65 years
• Cervical dystonia in adults, in toxin-naive and previously treated patients
• Upper limb spasticity in adults and in pediatric patients 2 years and older
• Lower limb spasticity in adults and in pediatric patients 2 years and older

Any use outside these indications is off-label and is a clinician judgment made case by case; it is not a use this product is promoted for. Dosing units are specific to this preparation. Units of Dysport are not interchangeable with units of other botulinum toxin products, and converting a dose from one brand to another by simple ratio is not supported by the labeling.

Why it matters: a unit is not a universal measure, so staff who stock more than one toxin should keep dosing references product-specific.

Choosing between 300 Unit and 500 Unit vials

Both presentations contain the same active ingredient and differ in total units per vial. The practical choice is usually driven by case mix and throughput rather than preference.

• 300 Unit vials suit lower-volume aesthetic schedules, single-session glabellar treatment and clinics that prefer less unused product per session.
• 500 Unit vials suit higher-volume injection days and spasticity or cervical dystonia cases, where total dose per patient is larger.

Because reconstituted product has a limited refrigerated shelf life, many clinics plan vial size around how many patients are booked in the same session. Clinics that buy Dysport wholesale often hold a mix of both sizes so a light day does not force opening a larger vial. Select the vial size needed during ordering and match it to the dosing plan and treatment schedule your clinicians use.

Patient selection, contraindications and precautions

Screening happens before reconstitution, not after. The prescribing information lists clear contraindications:

• Known hypersensitivity to any botulinum toxin preparation or to any component of the formulation
• Known allergy to cow’s milk protein, since the product contains lactose derived from cow’s milk
• Infection at the proposed injection site or sites

Added caution applies to patients with pre-existing neuromuscular disorders such as myasthenia gravis, Lambert-Eaton syndrome or amyotrophic lateral sclerosis, who may be more sensitive to toxin effects including swallowing and breathing difficulty. Patients with existing dysphagia or compromised respiratory status, and those with inflammation or marked weakness in the target muscle, also need careful assessment. Document pregnancy status, prior toxin exposure, prior treatment response and the interval since the last toxin injection.

Interaction risk centers on anything that affects neuromuscular transmission. Aminoglycoside antibiotics, curare-like muscle relaxants, anticholinesterases and other agents that interfere with the neuromuscular junction may potentiate the effect. Giving another botulinum toxin product within a few months of treatment can produce additive weakness, so the medication history should capture brand and date.

Distant spread warning, adverse reactions and monitoring

Dysport carries a boxed warning for distant spread of toxin effect. Symptoms consistent with botulinum toxin action, including asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulty, have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening, and the risk is greatest in children treated for spasticity. Patients and caregivers should be told to seek urgent care if these symptoms appear.

Common adverse reactions differ by indication. In glabellar line treatment, reported effects include nasopharyngitis, headache, injection site pain or reaction, sinusitis, nausea and eyelid ptosis. In cervical dystonia, muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue and headache are reported. In spasticity, muscular weakness, fatigue and falls are reported. Hypersensitivity reactions, including anaphylaxis, have occurred, so clinics should keep emergency management supplies in the treatment room.

Monitoring is clinical and interval-based. Review swallowing, speech, eyelid position and limb strength at follow-up, record the dose and sites used for each session, and compare response before adjusting the next treatment plan. Advise patients to contact the clinic for new weakness, vision change, voice change or difficulty swallowing rather than waiting for the scheduled visit.

Reconstitution, cold chain and receiving checks

Unopened vials are stored in the refrigerator at 2°C to 8°C and protected from light, per the prescribing information. Reconstitution uses 0.9% sodium chloride injection following the dilution table in the labeling for the indication being treated; the reconstituted solution is kept at 2°C to 8°C and used within 24 hours, then discarded. Preparation should follow aseptic technique in a clean, dedicated area.

A short receiving routine protects both the product and the record:

• Confirm the shipment is still cold on arrival and move vials to refrigerated storage promptly
• Check vial count, presentation and lot number against the packing documentation
• Record lot and expiry at receipt, and again in the patient chart at administration
• Log refrigerator temperatures and keep toxin stock separate from reconstituted preparations
• Rotate stock by expiry date and track opened-vial times during busy injection days

Med Wholesale Supplies is a wholesale supplier of aesthetic, orthopedic and medical products to clinics, hospitals and medical professionals, operating since 2013. Products are supplied through licensed pharmacy channels, and clinic documentation or professional-use ordering requirements may apply; we may review order details before an order is finalized.

How Dysport compares with other botulinum toxin type A products

Dysport, onabotulinumtoxinA and incobotulinumtoxinA are all botulinum toxin type A products, but they are distinct biologics with their own labeling, dosing units, dilution tables and approved indications. They are not generic versions of each other and are not interchangeable in practice or on the order sheet.

Practical differences that matter to a clinic buyer include vial sizes available, approved indications for the patient groups you treat, reconstitution volumes and storage instructions, and whether the formulation contains cow’s milk protein, which is relevant to allergy screening. Clinics that buy Dysport wholesale alongside another neuromodulator should keep separate dosing references and separate storage labeling to reduce the chance of a unit-for-unit error.

Quick tip: keep a product-specific dilution and dosing card on the fridge door for each toxin your clinic stocks.

Nothing here replaces the manufacturer’s instructions for use or the FDA-approved prescribing information, which remain the controlling reference for dosing, dilution, storage and administration.

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.